Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 6Withdrawn 2Recruiting 2Not yet recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 54Other hematologic neoplasm 13Genitourinary 11Plasma cell 5Myeloid 2CNS 2Endocrine 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Nivolumab 25pembrolizumab 21Ipilimumab 15Temozolomide 13toripalimab 12Biopsy 10Imiquimod 8Cyclophosphamide 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4fludarabine 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Injections 4Bevacizumab 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Prednisone × Dermatologic × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡